Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kobayashi And Osaka University Found Antioxidants From Shiitake Essence Inhibit Hepatitis Symptoms

This article was originally published in PharmAsia News

Executive Summary

Kobayashi Pharmaceutical Co. and Osaka University discovered two antioxidants that inhibit Hepatitis symptoms. The substances under research, syringic acid and vallinic acid, are extracted from the essence of Shiitake Mushroom mycelium. The onset of symptoms was delayed and progress of liver fabrication decreased in mice with hepatitis symptoms following treatment with the antioxidants. The universities plan on developing a new drug from the antioxidants that will protect liver cells and could be combined with antivirus drugs such as interferon to prevent cirrhosis and liver cancer. (Click for more-Japanese language) "Kobayashi And Osaka University Found Shiitake Essence Inhibit Hepatitis Symptoms And Confirm Through Test on Mice" - Nikan Industrial News (2/18/08)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067710

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel